Pharmacological and Genetic Perturbation Establish SIRT5 as a Promising Target in Breast Cancer

[1]  J. Erickson,et al.  SIRT5 stabilizes mitochondrial glutaminase and supports breast cancer tumorigenesis , 2019, Proceedings of the National Academy of Sciences.

[2]  N. Curtin,et al.  Warburg and Krebs and related effects in cancer , 2019, Expert Reviews in Molecular Medicine.

[3]  M. Gnant,et al.  Breast cancer , 2019, Nature Reviews Disease Primers.

[4]  Hening Lin,et al.  Novel Lysine-Based Thioureas as Mechanism-Based Inhibitors of Sirtuin 2 (SIRT2) with Anticancer Activity in a Colorectal Cancer Murine Model. , 2019, Journal of medicinal chemistry.

[5]  Hening Lin,et al.  A Small‐Molecule SIRT2 Inhibitor That Promotes K‐Ras4a Lysine Fatty‐Acylation , 2019, ChemMedChem.

[6]  Weiping Zheng,et al.  Cyclic tripeptide-based potent and selective human SIRT5 inhibitors. , 2019, Medicinal chemistry (Shariqah (United Arab Emirates)).

[7]  Ji Cao,et al.  Direct Comparison of SIRT2 Inhibitors: Potency, Specificity, Activity‐Dependent Inhibition, and On‐Target Anticancer Activities , 2018, ChemMedChem.

[8]  Ce Li,et al.  SIRT5 as a biomarker for response to anthracycline-taxane-based neoadjuvant chemotherapy in triple-negative breast cancer. , 2018, Oncology reports.

[9]  W. Sippl,et al.  Potent and Selective Inhibitors of Human Sirtuin 5. , 2018, Journal of medicinal chemistry.

[10]  Jie Xu,et al.  Sirtuin5 contributes to colorectal carcinogenesis by enhancing glutaminolysis in a deglutarylation-dependent manner , 2018, Nature Communications.

[11]  Zhe Wang,et al.  SHMT2 Desuccinylation by SIRT5 Drives Cancer Cell Proliferation. , 2018, Cancer research.

[12]  Liang Chang,et al.  SIRT5 promotes cell proliferation and invasion in hepatocellular carcinoma by targeting E2F1. , 2017, Molecular medicine reports.

[13]  C. Steegborn,et al.  Mechanism-Based Inhibitors of the Human Sirtuin 5 Deacylase: Structure-Activity Relationship, Biostructural, and Kinetic Insight. , 2017, Angewandte Chemie.

[14]  Laura G. Dubois,et al.  A Class of Reactive Acyl-CoA Species Reveals the Non-enzymatic Origins of Protein Acylation. , 2017, Cell metabolism.

[15]  X. Niu,et al.  Desuccinylation of pyruvate kinase M2 by SIRT5 contributes to antioxidant response and tumor growth , 2016, Oncotarget.

[16]  Yajun Huang,et al.  A Selective Cyclic Peptidic Human SIRT5 Inhibitor , 2016, Molecules.

[17]  E. Borazan,et al.  High-throughput screening of Sirtuin family of genes in breast cancer. , 2016, Gene.

[18]  Hening Lin,et al.  The Substrate Specificity of Sirtuins. , 2016, Annual review of biochemistry.

[19]  Y. Xiong,et al.  SIRT5 promotes IDH2 desuccinylation and G6PD deglutarylation to enhance cellular antioxidant defense , 2016, EMBO reports.

[20]  Christian M. Metallo,et al.  Reductive carboxylation supports redox homeostasis during anchorage-independent growth , 2016, Nature.

[21]  Johan Auwerx,et al.  Metabolomics-assisted proteomics identifies succinylation and SIRT5 as important regulators of cardiac function , 2016, Proceedings of the National Academy of Sciences.

[22]  Hening Lin,et al.  A SIRT2-Selective Inhibitor Promotes c-Myc Oncoprotein Degradation and Exhibits Broad Anticancer Activity. , 2016, Cancer cell.

[23]  P. Giannakakou,et al.  A SIRT2-Selective Inhibitor Promotes c-Myc Oncoprotein Degradation and Exhibits Broad Anticancer Activity. , 2016, Cancer cell.

[24]  Steven J. M. Jones,et al.  Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer , 2015, Cell.

[25]  Matthew J. Rardin,et al.  SIRT5 Regulates both Cytosolic and Mitochondrial Protein Malonylation with Glycolysis as a Major Target. , 2015, Molecular cell.

[26]  Yingming Zhao,et al.  Metabolic Regulation by Lysine Malonylation, Succinylation, and Glutarylation* , 2015, Molecular & Cellular Proteomics.

[27]  M. Russo,et al.  SIRT5 regulation of ammonia-induced autophagy and mitophagy , 2015, Autophagy.

[28]  Min Zhang,et al.  SIRT5 facilitates cancer cell growth and drug resistance in non-small cell lung cancer , 2014, Tumor Biology.

[29]  M. Hirschey,et al.  Nonenzymatic protein acylation as a carbon stress regulated by sirtuin deacylases. , 2014, Molecular cell.

[30]  Yingming Zhao,et al.  Lysine glutarylation is a protein posttranslational modification regulated by SIRT5. , 2014, Cell metabolism.

[31]  Mong-Hong Lee,et al.  Cancer metabolic reprogramming: importance, main features, and potentials for precise targeted anti-cancer therapies , 2014, Cancer biology & medicine.

[32]  Matthew J. Rardin,et al.  SIRT5 regulates the mitochondrial lysine succinylome and metabolic networks. , 2013, Cell metabolism.

[33]  X. Chen,et al.  SIRT5 desuccinylates and activates SOD1 to eliminate ROS. , 2013, Biochemical and biophysical research communications.

[34]  J. Auwerx,et al.  Metabolic Characterization of a Sirt5 deficient mouse model , 2013, Scientific Reports.

[35]  Yingming Zhao,et al.  SIRT5-mediated lysine desuccinylation impacts diverse metabolic pathways. , 2013, Molecular cell.

[36]  A. Snowman,et al.  Inositol Polyphosphate Multikinase Is a Coactivator of p53-Mediated Transcription and Cell Death , 2013, Science Signaling.

[37]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[38]  A. Regev,et al.  The Histone Deacetylase SIRT6 Is a Tumor Suppressor that Controls Cancer Metabolism , 2012, Cell.

[39]  Tobias Rumpf,et al.  Inhibitors of the NAD(+)-Dependent Protein Desuccinylase and Demalonylase Sirt5. , 2012, ACS medicinal chemistry letters.

[40]  Hening Lin,et al.  Protein lysine acylation and cysteine succination by intermediates of energy metabolism. , 2012, ACS chemical biology.

[41]  Johan Auwerx,et al.  Sirtuins as regulators of metabolism and healthspan , 2012, Nature Reviews Molecular Cell Biology.

[42]  Hening Lin,et al.  Thiosuccinyl peptides as Sirt5-specific inhibitors. , 2012, Journal of the American Chemical Society.

[43]  Balaraman Kalyanaraman,et al.  Measuring reactive oxygen and nitrogen species with fluorescent probes: challenges and limitations. , 2012, Free radical biology & medicine.

[44]  Johan Auwerx,et al.  Sirt5 Is a NAD-Dependent Protein Lysine Demalonylase and Desuccinylase , 2011, Science.

[45]  Yi Zhang,et al.  The First Identification of Lysine Malonylation Substrates and Its Regulatory Enzyme* , 2011, Molecular & Cellular Proteomics.

[46]  P. Pandolfi,et al.  SIRT3 opposes reprogramming of cancer cell metabolism through HIF1α destabilization. , 2011, Cancer cell.

[47]  Hanna Y. Irie,et al.  Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment , 2009, Nature.

[48]  Brian C. Smith,et al.  Mechanism-based inhibition of Sir2 deacetylases by thioacetyl-lysine peptide. , 2007, Biochemistry.

[49]  Zhiyuan Hu,et al.  Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors , 2007, Genome Biology.

[50]  H. Iwase,et al.  [Breast cancer]. , 2006, Nihon rinsho. Japanese journal of clinical medicine.

[51]  Jeffrey W Pollard,et al.  Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. , 2003, The American journal of pathology.

[52]  T. Jacks,et al.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. , 2001, Genes & development.

[53]  R. Cardiff,et al.  The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting‡ , 2000, Oncogene.

[54]  L. Guarente,et al.  Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase , 2000, Nature.

[55]  R. Cardiff,et al.  Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease , 1992, Molecular and cellular biology.